Lapatinib Resistance in Breast Cancer Cells Is Accompanied by Phosphorylation-Mediated Reprogramming of Glycolysis.
暂无分享,去创建一个
Bernhard Kuster | Wei Wu | Simone Lemeer | B. Kuster | S. Lemeer | Benjamin Ruprecht | Wei Wu | C. Berkers | Celia R. Berkers | Jana Zecha | Benjamin Ruprecht | Esther A. Zaal | J. Zecha | E. Zaal
[1] E. Wiemer,et al. The spliceosome as target for anticancer treatment , 2008, British Journal of Cancer.
[2] K. Carraway,et al. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. , 2008, Cancer research.
[3] Maxime Caron,et al. ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer , 2016, Nature Communications.
[4] J. Camonis,et al. A yeast two‐hybrid study of human p97/Gab2 interactions with its SH2 domain‐containing binding partners , 2001, FEBS letters.
[5] M Tan,et al. Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth , 2009, Oncogene.
[6] Graham Ball,et al. Untangling the ATR‐CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer , 2015, Molecular oncology.
[7] S. Asa,et al. The breast cancer susceptibility FGFR2 provides an alternate mode of HER2 activation. , 2015, Oncogene.
[8] Hua Guo,et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways , 2011, Nature Medicine.
[9] R. Schiff,et al. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells , 2015, Cell cycle.
[10] C R King,et al. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.
[11] Marco Y. Hein,et al. The Perseus computational platform for comprehensive analysis of (prote)omics data , 2016, Nature Methods.
[12] Lei Wang,et al. RON confers lapatinib resistance in HER2-positive breast cancer cells. , 2013, Cancer letters.
[13] M. Guarino. Src signaling in cancer invasion , 2010, Journal of cellular physiology.
[14] Yun Wu,et al. Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. , 2011, Cancer research.
[15] L. Korotchkina,et al. Probing the Mechanism of Inactivation of Human Pyruvate Dehydrogenase by Phosphorylation of Three Sites* , 2001, The Journal of Biological Chemistry.
[16] D. Hanahan,et al. Hijacking the Neuronal NMDAR Signaling Circuit to Promote Tumor Growth and Invasion , 2013, Cell.
[17] S. Hanash,et al. EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. , 2016, Cancer research.
[18] Heiner Koch,et al. Comprehensive and Reproducible Phosphopeptide Enrichment Using Iron Immobilized Metal Ion Affinity Chromatography (Fe-IMAC) Columns , 2014, Molecular & Cellular Proteomics.
[19] William Pao,et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase , 2011, Proceedings of the National Academy of Sciences.
[20] M. Hagiwara,et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA , 2007, Nature Chemical Biology.
[21] Joel Greshock,et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. , 2009, Cancer research.
[22] D. Carling,et al. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia , 2000, Current Biology.
[23] S. Braun,et al. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors , 2013, Leukemia.
[24] C. Le Page,et al. PRP4K is a HER2-regulated modifier of taxane sensitivity , 2015, Cell cycle.
[25] Naoto T. Ueno,et al. P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells , 2004, Cancer Research.
[26] G. Dellaire,et al. Estrogen receptor alpha (ESR1)-signaling regulates the expression of the taxane-response biomarker PRP4K. , 2016, Experimental cell research.
[27] Carlos L Arteaga,et al. Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network , 2007, Clinical Cancer Research.
[28] Jonathan A. Cooper,et al. Three glycolytic enzymes are phosphorylated at tyrosine in cells transformed by Rous sarcoma virus , 1983, Nature.
[29] B. Kuster,et al. Evaluation of Kinase Activity Profiling Using Chemical Proteomics. , 2015, ACS chemical biology.
[30] Ryuji Kobayashi,et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. , 2005, Cancer research.
[31] A. Bode,et al. Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib , 2014, Cell cycle.
[32] J. Gustafsson,et al. ERβ decreases breast cancer cell survival by regulating the IRE1/XBP-1 pathway , 2014, Oncogene.
[33] Sean J. Humphrey,et al. Protein Phosphorylation: A Major Switch Mechanism for Metabolic Regulation , 2015, Trends in Endocrinology & Metabolism.
[34] Lu Xie,et al. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. , 2010, Cancer research.
[35] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[36] C. Lange,et al. Progesterone receptor action: defining a role in breast cancer , 2011, Expert review of endocrinology & metabolism.
[37] W. Hahn,et al. PRKACA Mediates Resistance to HER2-Targeted Therapy in Breast Cancer Cells and Restores Anti-Apoptotic Signaling , 2014, Oncogene.
[38] Z. Fei,et al. Integrative bioinformatics and proteomics-based discovery of an eEF2K inhibitor (cefatrizine) with ER stress modulation in breast cancer cells. , 2016, Molecular bioSystems.
[39] Tyler J Moss,et al. The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells , 2012, Molecular systems biology.
[40] F. Khuri,et al. Tyrosine Phosphorylation of Lactate Dehydrogenase A Is Important for NADH/NAD+ Redox Homeostasis in Cancer Cells , 2011, Molecular and Cellular Biology.
[41] Reinout Raijmakers,et al. Multiplex peptide stable isotope dimethyl labeling for quantitative proteomics , 2009, Nature Protocols.
[42] P. Hegde,et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[43] M. Berger,et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.
[44] M. Mann,et al. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.
[45] Alexander Levitzki,et al. Therapeutic destruction of insulin receptor substrates for cancer treatment. , 2013, Cancer research.
[46] T. Shimokawa,et al. SHIP2 and its involvement in various diseases , 2010, Expert opinion on therapeutic targets.
[47] G. Omenn,et al. Proteomic characterization of novel alternative splice variant proteins in human epidermal growth factor receptor 2/neu-induced breast cancers. , 2010, Cancer research.
[48] Wayne A. Phillips,et al. Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.
[49] Jeff S. Jasper,et al. ERRα-Regulated Lactate Metabolism Contributes to Resistance to Targeted Therapies in Breast Cancer. , 2016, Cell reports.
[50] C. J. O’Donnell,et al. Spliceostatin hemiketal biosynthesis in Burkholderia spp. is catalyzed by an iron/α-ketoglutarate–dependent dioxygenase , 2014, Proceedings of the National Academy of Sciences.
[51] Y. Lu,et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). , 2001, Journal of the National Cancer Institute.
[52] B. Kuster,et al. Optimized chemical proteomics assay for kinase inhibitor profiling. , 2015, Journal of proteome research.
[53] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[54] G. Mills,et al. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition , 2011, Oncogene.
[55] A. Kazlauskas,et al. Lactate Engages Receptor Tyrosine Kinases Axl, Tie2, and Vascular Endothelial Growth Factor Receptor 2 to Activate Phosphoinositide 3-Kinase/Akt and Promote Angiogenesis* , 2013, The Journal of Biological Chemistry.